FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Yutaka Hasegawa

Research Profile

Chemicals & Drugs

Disorders

Physiology

Phenomena

Hydrolysis

Anatomy

Procedures

Genetic Therapy

Living Beings

Mouse

Co-author Network

Publications

TOP 3
Yutaka Hasegawa; Mandi Murph; Shuangxing Yu; Gabor Tigyi; Gordon B Mills
Lysophosphatidic acid (LPA)-induced vasodilator-stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC-3 prostate cancer cells.
Shuying Liu; Shuangxing Yu; Yutaka Hasegawa; Ruth Lapushin; Hong-Ji Xu; James R Woodgett; Gordon B Mills; Xianjun Fang
Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase.
Makiko Umezu-Goto; Janos L Tanyi; John Lahad; Shuying Liu; Shuangxing Yu; Ruth Lapushin; Yutaka Hasegawa; Yiling Lu; Rosanne Trost; Therese Bevers; Eric Jonasch; Kenneth Aldape; Jinsong Liu; Robyn D James; Colin G Ferguson; Yong Xu; Glenn D Prestwich; Gordon B Mills
Lysophosphatidic acid production and action: validated targets in cancer?

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Yutaka Hasegawa (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Yutaka Hasegawa; Mandi Murph; Shuangxing Yu; Gabor Tigyi; Gordon B Mills
Lysophosphatidic acid (LPA)-induced vasodilator-stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC-3 prostate cancer cells.
Molecular oncology 2008;2(1):54-69.
2004: Shuying Liu; Shuangxing Yu; Yutaka Hasegawa; Ruth Lapushin; Hong-Ji Xu; James R Woodgett; Gordon B Mills; Xianjun Fang
Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase.
The Journal of biological chemistry 2004;279(49):51075-81.
2004: Makiko Umezu-Goto; Janos L Tanyi; John Lahad; Shuying Liu; Shuangxing Yu; Ruth Lapushin; Yutaka Hasegawa; Yiling Lu; Rosanne Trost; Therese Bevers; Eric Jonasch; Kenneth Aldape; Jinsong Liu; Robyn D James; Colin G Ferguson; Yong Xu; Glenn D Prestwich; Gordon B Mills
Lysophosphatidic acid production and action: validated targets in cancer?
Journal of cellular biochemistry 2004;92(6):1115-40.
2003: Janos L Tanyi; Yutaka Hasegawa; Ruth Lapushin; Andrew J Morris; Judith K Wolf; Andrew Berchuck; Karen Lu; David I Smith; Kimberly R Kalli; Lynn C Hartmann; Karen McCune; David Fishman; Russell R Broaddus; Kwai Wa Cheng; E Neely Atkinson; Jose-Miguel Yamal; Robert C Bast; Edward Felix; Robert A Newman; Gordon B Mills
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3534-45.
2003: Yutaka Hasegawa; James R Erickson; Graham J Goddard; Shuangxing Yu; Shuying Liu; Kwai Wa Cheng; Astrid Eder; Koji Bandoh; Junken Aoki; Renata Jarosz; Andrew D Schrier; Kevin R Lynch; Gordon B Mills; Xianjun Fang
Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor.
The Journal of biological chemistry 2003;278(14):11962-9.
2003: Janos L Tanyi; Andrew J Morris; Judith K Wolf; Xianjun Fang; Yutaka Hasegawa; Ruth Lapushin; Nelly Auersperg; Yury J Sigal; Robert A Newman; Edward Felix; E Neely Atkinson; Gordon B Mills
The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer.
Cancer research 2003;63(5):1073-82.
2003: Gordon B Mills; Xianjun Fang; Yiling Lu; Yutaka Hasegawa; Astrid Eder; Janos L Tanyi; Fazal H Tabassam; Muling Mao; Hongwei Wang; Kwai Wa Cheng; Yasuhisa Nakayama; Wenlin Kuo; Jim Erickson; David M Gershenson; Elise C Kohn; Robert Jaffe; Robert C Bast; Joe Gray
Specific keynote: molecular therapeutics in ovarian cancer.
Gynecologic oncology 2003;88(1 Pt 2):S88-92; discussion S93-6.
2002: Xianjun Fang; Michel Schummer; Muling Mao; Shuangxing Yu; Fazal H Tabassam; Ramona Swaby; Yutaka Hasegawa; Janos L Tanyi; Ruth Lapushin; Astrid Eder; Robert Jaffe; Jim Erickson; Gordon B Mills
Lysophosphatidic acid is a bioactive mediator in ovarian cancer.
Biochimica et biophysica acta 2002;1582(1-3):257-64.
2002: Gordon B Mills; Astrid Eder; Xianjun Fang; Yutaka Hasegawa; Muling Mao; Yiling Lu; Janos L Tanyi; Fazal H Tabassam; Jon R Wiener; Ruth Lapushin; Shiangxing Yu; Jeff A Parrott; Tim Compton; Walter Tribley; David Fishman; M Sharon Stack; Douglas Gaudette; Robert Jaffe; Tatsuro Furui; Junken Aoki; James R Erickson
Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer.
Cancer treatment and research 2002;107():259-83.
2001: James R Erickson; Yutaka Hasegawa; Xiang Fang; Astrid Eder; Muling Mao; Tatsuro Furui; Junken Aoki; Andrew J Morris; Gordon B Mills
Lysophosphatidic acid and ovarian cancer: a paradigm for tumorogenesis and patient management.
Prostaglandins & other lipid mediators 2001;64(1-4):63-81.